https://sciex.com/content/SCIEX/na/us/en


Three Infographics to Show You How to Overcome Challenges in Transitioning to Biologics Bioanalysis

Jul 8, 2016 | Biopharma, Blogs | 0 comments

The move to large molecules in Pharma is accelerating, offering unprecedented opportunities to improve human health and expand into new markets. But for those with extensive experience with small molecule bioanalysis, the shift to biologics can be challenging, from Sample Prep to Instrumentation and Software, to Methods and Training:

  • Sample Prep is complex
    • Every new biologic requires a specific sample prep strategy: sourcing reagents and researching protocols
    • Bioanalysis studies have large sample numbers
    • Tedious manual steps for enrichment, digestion, and clean-up can result in high variability
  • Instrumentation and Software have to be up to the task
    • Efficient MRM optimization is required for chromatography, multiple charge states, declustering potential and collision energy
    • Maximal sensitivity is needed for low abundance samples
    • Enhanced selectivity is important to overcome matrix interference
    • Simple software for complex data is essential, which can handle large sample sets and batches
  • Methods and Training are needed to get running quickly
    • You have to develop your sample prep protocol, source reagents and optimize your LC-MS methods, which can take months
    • You have to train your scientists to understand and run the new methods: how are you going to do it?

The challenges seem daunting, but SCIEX can help you overcome them with relative ease.  Download a three-part infographic that addresses all three challenges and describes the solutions with links to useful reference material.  The SCIEX BioBA Solution will get you up and running quickly and painlessly.Download Infographic >

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial